Macrophage-Derived EV Composition for Erythroid Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for in vitro erythrocyte generation face inefficiencies in proliferation, differentiation, and enucleation, and there is a lack of understanding of the interaction between macrophages and erythroid precursor cells, which limits the yield of erythrocyte production needed for blood supply.
Innovation Solution
The use of macrophage-derived extracellular vesicles (EVs) to promote the differentiation and maturation of erythroid precursor cells into erythrocytes by regulating erythropoiesis through direct interaction or intracellular signaling, increasing the expression of adhesion proteins and markers like ICAM4 and AHSP.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional in vitro methods are used for erythrocyte generation, then the process can be performed with existing technology, but the efficiency of proliferation, differentiation, and enucleation is insufficient
Solution Approach 1:
The patent introduces macrophage-derived extracellular vesicles (EVs) as an intermediary substance to mediate the interaction between macrophages and erythroid precursor cells. These EVs carry bioactive molecules including nucleic acids and proteins that regulate erythropoiesis, thereby improving differentiation efficiency without requiring direct cell-to-cell contact. This mediator approach resolves the contradiction by enhancing reliability through targeted molecular delivery while maintaining productivity through scalable EV production.
Solution Approach 2:
The patent changes the biochemical parameters of the culture system by adding macrophage-derived EVs containing specific proteins and nucleic acids. This parameter change triggers enhanced differentiation signals in erythroid precursor cells, improving both the efficiency and reliability of erythrocyte production. The EVs modify the chemical composition of the culture environment to optimize cellular responses.
2Quantity of substance
If the number of blood donors decreases due to aging population, then blood supply becomes insufficient, but increasing in vitro production may not meet clinical demands with current methods
Solution Approach 1:
By using macrophage-derived EVs as intermediaries, the patent enables highly efficient erythrocyte production from precursor cells. The EVs deliver concentrated signals that accelerate differentiation and enucleation processes, thereby increasing the production rate of erythrocytes in vitro. This mediator system allows for scalable production that can meet clinical blood supply demands independent of donor availability.
Solution Approach 2:
The patent employs preliminary action by pre-differentiating cells to erythroid precursor cells before applying the EV treatment. This preliminary preparation optimizes the cells' responsiveness to EV signals, enabling faster and more efficient maturation into erythrocytes. The staged approach with preliminary differentiation followed by EV-induced maturation accelerates overall production throughput.
Data Source
Figure 1A
Figure 1B~1C
Figure 2A~2B
AI summary
The present invention relates to a composition for inducing differentiation in erythroid precursor cells and, more specifically, to: a composition comprising macrophage-derived extracellular vesicles for inducing differentiation of erythroid precursor cells; and a method for inducing differentiation into erythrocyte by treating erythroid precursor cells with macrophage-derived extracellular vesicles.